Infants and young children with bronchopulmonary dysplasia (BPD) and/or a history of prematurity are at high risk for serious RSV disease. Previous studies have suggested that RSV-IGIV may effectively reduce this risk. A randomized double-blind, placebo-controlled trial (PREVENT) was conducted to define the efficacy and safety of monthly RSV-IGIV prophylaxis in premature/BPD patients. Between 11/15/94 and 12/22/94, 510 children were randomized (260 placebo, 250 RSV-IGIV) at 54 centers in the US. Mean age at enrollment was 5.8 months (range, 0.1-23.8 months); mean gestational age at birth was 28.5 weeks; 60% had BPD and an O2 requirement within 6 months of randomization. Children received monthly intravenous infusions of 750 mg/kg RSV-IGIV or placebo (albumin) during the RSV season. Approximately 95% of children completed the protocol and 85% received a full course of study agent(4 or 5 infusions). RSV-IGIV prophylaxis was associated with a 41% reduction in RSV hospitalization (35/260 placebo vs 20/250 RSV-IGIV, p=0.047); 53% reduction in total days of RSV hospitalization/100 children (129 placebo vs 60 RSV-IGIV, p=0.045); 60% reduction in RSV hospital days with increased O2 requirement/100 children (85 vs 34, p=0.007); and 54% reduction in RSV hospital days with a moderate/severe lower respiratory tract infection(106 vs 49, p=0.049). RSV-IGIV recipients also had a 38% reduction in hospitalization for any respiratory illness (69/260 vs 41/250, p=0.005) and a 46% reduction in total days of respiratory illness hospitalization per 100 children (317 vs 170, p=0.005). RSV-IGIV infusions were well tolerated, with a safety profile similar to other intravenous immunoglobulin preparations. Between 1-3% of children had significant adverse experiences attributable to the treatment (fluid complications, fever, acute reactions). RSV-IGIV was safe and effective for the prevention of serious RSV disease in high-risk children with BPD and/or a history of prematurity. Funded by MedImmune, Inc.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Connor, E., for the PREVENT Study Group. REDUCTION OF RESPIRATORY SYNCYTIAL VIRUS-ASSOCIATED HOSPITALIZATION IN CHILDREN WITH PREMATURE BIRTH AND /OR BRONCHOPULMONARY DYSPLASIA USING MONTHLY INFUSIONS OF RSV IMMUNE GLOBULIN (RespiGam, RSV-IGIV). • 100. Pediatr Res 39 (Suppl 4), 169 (1996). https://doi.org/10.1203/00006450-199604001-01022
Issue Date:
DOI: https://doi.org/10.1203/00006450-199604001-01022